mitochondrial ribosomal protein L48 pseudogene 1Genealiases: MRPL48L1 · dJ290I10.4
Q-omics provides the consensus-scored MRPL48P1 profile across patient tissues and cancer cell-line models. MRPL48P1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPL48P1 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, MRPL48P1 RNA expression shows 9,761 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where MRPL48P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL48P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL48P1 survival associations across molecular data types. MRPL48P1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL48P1 RNA expression–survival associations across cancer types. High MRPL48P1 expression shows unfavorable associations in KIRC, UCS and CHOL, but favorable associations in UVM, THCA and STAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for MRPL48P1 RNA expression.
This table summarizes MRPL48P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MRPL48P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL48P1 shows higher tumor expression in COAD, LUSC, HNSC, PAAD, UCEC and BLCA. The COAD box plot shows higher MRPL48P1 RNA expression in tumor versus normal tissue (log2 FC = +0.156, t-test p < 0.001).
This table shows molecular features associated with MRPL48P1 in patient tissues and cancer cell lines. In patient samples, MRPL48P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
